{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-229767","form_type":"8-K","ticker":"BLCO","cik":"0001860742","company_name":"Bausch & Lomb Corp","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.854636+00:00","generated_at":"2026-06-10T23:37:41.922231+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bausch + Lomb provides financials for Novartis XIIDRA acquisition; $1.75B upfront plus $750M milestones","bullets":["Acquisition of XIIDRA (lifitegrast) and certain ophthalmology assets from Novartis for $1.75B upfront and up to $750M milestone payments.","Closing expected at or around end of September 2023, subject to customary conditions.","Acquired assets had net revenue of $487M in 2022 and $468M in 2021, with total comprehensive shortfall of $384M in 2022.","Net assets acquired were $2.065B as of Dec 31, 2022, including $2.138B intangible asset."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-229767","json":"https://secwatch.observer/filing/0001193125-23-229767.json","markdown":"https://secwatch.observer/filing/0001193125-23-229767.md","text":"https://secwatch.observer/filing/0001193125-23-229767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/0001193125-23-229767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/d548500d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:37:41.922231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}